Cardiorenal syndrome revisited

F Zannad, P Rossignol - Circulation, 2018 - Am Heart Assoc
Cardiorenal syndromes have been categorized into 5 clinical subtypes based on which
organ is perceived to be the primary precipitant of the vicious and interrelated cycle of …

Cardiac remodeling at the population level—risk factors, screening, and outcomes

O Gjesdal, DA Bluemke, JA Lima - Nature Reviews Cardiology, 2011 - nature.com
The prevalence of heart failure is increasing in the western world. Current efforts aim to
identify heart failure at its earliest and preclinical stages in order to begin treatment and …

Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study

D Tientcheu, C Ayers, SR Das, DK McGuire… - Journal of the American …, 2015 - jacc.org
Background: Multiple epidemiological studies from Europe and Asia have demonstrated
increased cardiovascular risks associated with isolated elevation of home blood pressure …

Cystatin C and contrast-induced acute kidney injury

C Briguori, G Visconti, NV Rivera, A Focaccio, B Golia… - Circulation, 2010 - Am Heart Assoc
Background—Cystatin C (CyC) is more sensitive than serum creatinine (sCr) to rapidly
detect acute changes in renal function. Methods and Results—We measured CyC together …

Sex-based differences in cardiometabolic biomarkers

J Lew, M Sanghavi, CR Ayers, DK McGuire, T Omland… - Circulation, 2017 - Am Heart Assoc
Background: Few data are available comparing cardiovascular disease (CVD) biomarker
profiles between women and men in the general population. We analyzed sex-based …

Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival

WHW Tang, K Shrestha, Z Shao, AG Borowski… - The American journal of …, 2011 - Elsevier
Galectin-3 plays an important role in fibroblast activation and fibrosis in animal models.
Increased galectin-3 levels are associated with poor long-term survival in heart failure (HF) …

Cystatin C: an emerging biomarker in cardiovascular disease

C Angelidis, S Deftereos… - Current topics in …, 2013 - ingentaconnect.com
Cystatin C (cys-C) is a small protein molecule (120 amino acid peptide chain, approximately
13kDa) produced by virtually all nucleated cells in the human body. It belongs to the family …

The 2014 Canadian Cardiovascular Society heart failure management guidelines focus update: anemia, biomarkers, and recent therapeutic trial implications

GW Moe, JA Ezekowitz, E O'Meara, S Lepage… - Canadian Journal of …, 2015 - Elsevier
Abstract The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines
Update provides discussion on the management recommendations on 3 focused areas:(1) …

Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication

XW Cheng, GP Shi, M Kuzuya, T Sasaki, K Okumura… - Circulation, 2012 - Am Heart Assoc
The extracellular matrix (ECM) of the heart is composed largely of elastin and collagen and
plays many roles in cardiac wall and valve homeostasis. Maintenance of a healthy cardiac …

[HTML][HTML] Proteases in cardiometabolic diseases: Pathophysiology, molecular mechanisms and clinical applications

Y Hua, S Nair - Biochimica et Biophysica Acta (BBA)-Molecular Basis …, 2015 - Elsevier
Cardiovascular disease is the leading cause of death in the US and other developed
countries. Metabolic syndrome, including obesity, diabetes/insulin resistance, hypertension …